BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 20495567)

  • 1. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.
    Sheng Z; Li L; Zhu LJ; Smith TW; Demers A; Ross AH; Moser RP; Green MR
    Nat Med; 2010 Jun; 16(6):671-7. PubMed ID: 20495567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An activating transcription factor 5-mediated survival pathway as a target for cancer therapy?
    Sheng Z; Evans SK; Green MR
    Oncotarget; 2010 Oct; 1(6):457-460. PubMed ID: 21311102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATF5 promotes malignant T cell survival through the PI3K/AKT/mTOR pathway in cutaneous T cell lymphoma.
    Cao M; Lai P; Liu X; Liu F; Qin Y; Tu P; Wang Y
    Front Immunol; 2023; 14():1282996. PubMed ID: 38223508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance.
    Banerjee D; Boboila S; Okochi S; Angelastro JM; Kadenhe-Chiweshe AV; Lopez G; Califano A; Connolly EP; Greene LA; Yamashiro DJ
    Cancer Res Commun; 2023 Dec; 3(12):2518-2530. PubMed ID: 38014922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATF5 is a regulator of ER stress and β-cell apoptosis in different mouse models of genetic- and diet-induced obesity and diabetes mellitus.
    Ma J; Liu Y; Valladolid-Acebes I; Recio-López P; Peng G; Li J; Berggren PO; Juntti-Berggren L; Tong N
    Cell Signal; 2023 Feb; 102():110535. PubMed ID: 36436799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nescient helix-loop-helix 1 (Nhlh1) is a novel activating transcription factor 5 (ATF5) target gene in olfactory and vomeronasal sensory neurons in mice.
    Ishii C; Nakano H; Higashiseto R; Ooki Y; Umemura M; Takahashi S; Takahashi Y
    Cell Tissue Res; 2024 Apr; 396(1):85-94. PubMed ID: 38388750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of two activating transcription factor 5 isoforms in papillary thyroid carcinoma.
    Vicari L; La Rosa C; Forte S; Calabrese G; Colarossi C; Aiello E; Salluzzo S; Memeo L
    Onco Targets Ther; 2016; 9():6225-6231. PubMed ID: 27785070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATF5: development of oncogenic resistance to radiotherapy.
    Ishihara S; Haga H
    Aging (Albany NY); 2015 Jul; 7(7):453-4. PubMed ID: 26187904
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers.
    Greene LA; Zhou Q; Siegelin MD; Angelastro JM
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of activating transcription factor 5 in human rectal cancer.
    Kong X; Meng W; Zhou Z; Li Y; Zhou B; Wang R; Zhan L
    Exp Ther Med; 2011 Sep; 2(5):827-831. PubMed ID: 22977583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuronal-glioma cross-talk.
    Baek AE
    Sci Signal; 2023 May; 16(785):eadi6672. PubMed ID: 37192301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide profiling of interleukin-4 and STAT6 transcription factor regulation of human Th2 cell programming.
    Elo LL; Järvenpää H; Tuomela S; Raghav S; Ahlfors H; Laurila K; Gupta B; Lund RJ; Tahvanainen J; Hawkins RD; Oresic M; Lähdesmäki H; Rasool O; Rao KV; Aittokallio T; Lahesmaa R
    Immunity; 2010 Jun; 32(6):852-62. PubMed ID: 20620947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nanoparticle conjugation on gene silencing by RNA interference.
    Singh N; Agrawal A; Leung AK; Sharp PA; Bhatia SN
    J Am Chem Soc; 2010 Jun; 132(24):8241-3. PubMed ID: 20518524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives.
    Ghigna C; De Toledo M; Bonomi S; Valacca C; Gallo S; Apicella M; Eperon I; Tazi J; Biamonti G
    RNA Biol; 2010; 7(4):495-503. PubMed ID: 20864806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overlapping kinase and phosphatase docking site regulates activity of the retinoblastoma protein.
    Hirschi A; Cecchini M; Steinhardt RC; Schamber MR; Dick FA; Rubin SM
    Nat Struct Mol Biol; 2010 Sep; 17(9):1051-7. PubMed ID: 20694007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NRMT is an alpha-N-methyltransferase that methylates RCC1 and retinoblastoma protein.
    Tooley CE; Petkowski JJ; Muratore-Schroeder TL; Balsbaugh JL; Shabanowitz J; Sabat M; Minor W; Hunt DF; Macara IG
    Nature; 2010 Aug; 466(7310):1125-8. PubMed ID: 20668449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule inducers of insulin expression in pancreatic alpha-cells.
    Fomina-Yadlin D; Kubicek S; Walpita D; Dancik V; Hecksher-Sørensen J; Bittker JA; Sharifnia T; Shamji A; Clemons PA; Wagner BK; Schreiber SL
    Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15099-104. PubMed ID: 20696901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis.
    Godin JD; Colombo K; Molina-Calavita M; Keryer G; Zala D; Charrin BC; Dietrich P; Volvert ML; Guillemot F; Dragatsis I; Bellaiche Y; Saudou F; Nguyen L; Humbert S
    Neuron; 2010 Aug; 67(3):392-406. PubMed ID: 20696378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma.
    Young DD; Connelly CM; Grohmann C; Deiters A
    J Am Chem Soc; 2010 Jun; 132(23):7976-81. PubMed ID: 20527935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antibiotic selection marker for nematode transgenesis.
    Giordano-Santini R; Milstein S; Svrzikapa N; Tu D; Johnsen R; Baillie D; Vidal M; Dupuy D
    Nat Methods; 2010 Sep; 7(9):721-3. PubMed ID: 20729841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.